TWI315986B - Compositions and methods for treating or preventing pneumococcal infection - Google Patents

Compositions and methods for treating or preventing pneumococcal infection

Info

Publication number
TWI315986B
TWI315986B TW092131025A TW92131025A TWI315986B TW I315986 B TWI315986 B TW I315986B TW 092131025 A TW092131025 A TW 092131025A TW 92131025 A TW92131025 A TW 92131025A TW I315986 B TWI315986 B TW I315986B
Authority
TW
Taiwan
Prior art keywords
compositions
treating
methods
pneumococcal infection
preventing pneumococcal
Prior art date
Application number
TW092131025A
Other languages
English (en)
Chinese (zh)
Other versions
TW200418502A (en
Inventor
C Chen Michael
Chiou Chuang-Jiun
Li Zhongming
Chen Dong-Sheng
Original Assignee
Synergy America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergy America Inc filed Critical Synergy America Inc
Publication of TW200418502A publication Critical patent/TW200418502A/zh
Application granted granted Critical
Publication of TWI315986B publication Critical patent/TWI315986B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW092131025A 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection TWI315986B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42449702P 2002-11-07 2002-11-07

Publications (2)

Publication Number Publication Date
TW200418502A TW200418502A (en) 2004-10-01
TWI315986B true TWI315986B (en) 2009-10-21

Family

ID=32312819

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092131025A TWI315986B (en) 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection

Country Status (10)

Country Link
US (2) US7217791B2 (enExample)
EP (1) EP1558280B1 (enExample)
JP (3) JP2006506989A (enExample)
KR (1) KR20050086427A (enExample)
CN (1) CN100443116C (enExample)
AU (1) AU2003291365B2 (enExample)
CA (1) CA2504938C (enExample)
ES (1) ES2451620T3 (enExample)
TW (1) TWI315986B (enExample)
WO (1) WO2004043376A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008287286B2 (en) 2007-04-13 2013-10-10 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009094730A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
BRPI1009829A2 (pt) 2009-03-24 2016-11-16 Novartis Ag combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2550289A4 (en) 2010-03-12 2013-11-27 Childrens Medical Center NEW IMMUNOGENES AND METHODS FOR IDENTIFICATION AND SCREENING THEREOF
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CN115887627A (zh) * 2011-04-21 2023-04-04 洛克菲勒大学 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
KR20140033127A (ko) 2011-05-17 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애에 대한 백신
CN104114695B (zh) * 2011-10-05 2018-04-17 洛克菲勒大学 二聚噬菌体溶素
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
WO2014124228A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CN107106635B (zh) 2014-11-21 2021-10-08 俄克拉何马大学董事会 肺炎球菌溶血素突变体及其使用方法
GB201610599D0 (en) * 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AU2017388891C1 (en) 2016-12-30 2025-04-17 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3678654B1 (en) 2017-09-07 2024-06-26 Merck Sharp & Dohme LLC Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
TW202019470A (zh) 2018-09-12 2020-06-01 美商艾芬尼維克斯公司 多價肺炎球菌疫苗
KR20240099160A (ko) 2021-09-09 2024-06-28 아피니백스, 인크. 다가 폐렴구균 백신

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2160570T3 (es) * 1988-12-16 2001-11-16 Nederlanden Staat Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos.
WO1995016711A1 (es) * 1993-12-17 1995-06-22 Universidad De Oviedo Anticuerpos contra la neumolisina y sus aplicaciones
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
CA2297374A1 (en) * 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP2053126A1 (en) * 1998-07-27 2009-04-29 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
ATE318924T1 (de) * 1998-12-04 2006-03-15 Univ Manitoba Zwei-schritte-verfahren zur impfung gegen chlamydia
JP2002533124A (ja) * 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
CN1222619C (zh) * 1999-12-17 2005-10-12 惠氏控股公司 增强对单纯疱疹病毒疫苗应答的疫苗及其制药应用

Also Published As

Publication number Publication date
WO2004043376A2 (en) 2004-05-27
US20080199952A1 (en) 2008-08-21
CN100443116C (zh) 2008-12-17
US7217791B2 (en) 2007-05-15
TW200418502A (en) 2004-10-01
CA2504938A1 (en) 2004-05-27
US20040213803A1 (en) 2004-10-28
US7585669B2 (en) 2009-09-08
EP1558280A4 (en) 2007-08-29
ES2451620T3 (es) 2014-03-28
EP1558280A2 (en) 2005-08-03
JP2010057501A (ja) 2010-03-18
AU2003291365B2 (en) 2009-06-11
KR20050086427A (ko) 2005-08-30
JP2006506989A (ja) 2006-03-02
CN1711105A (zh) 2005-12-21
EP1558280B1 (en) 2014-01-08
WO2004043376A3 (en) 2004-10-14
HK1074005A1 (en) 2005-10-28
AU2003291365A1 (en) 2004-06-03
CA2504938C (en) 2011-10-11
JP2012139221A (ja) 2012-07-26

Similar Documents

Publication Publication Date Title
TWI315986B (en) Compositions and methods for treating or preventing pneumococcal infection
AU2002254158A1 (en) Medical devices, compositions and methods for treating vulnerable plaque
GB0110288D0 (en) Composition and treatment method
EP1628530A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SEPSIA
ZA200108215B (en) Compositions and methods for treatment of staphylococcal infection.
IL160010A0 (en) Methods and compositions for treating fungal infections
AU2002367023A8 (en) Compositions and methods for treating heart failure
EP1651255A4 (en) TOPICAL VETERINARY COMPOSITIONS AND METHODS OF TREATING AND PREVENTING INFECTIONS
AU2003297573A8 (en) Compositions and methods for treating transplants
SG118236A1 (en) Compositions and methods for treating coronavirus infection and SARS
EP1461047A4 (en) COMPOSITIONS AND METHODS FOR TREATING ANIMALS
AU2002365057A8 (en) Compositions and methods for treating heart failure
AU2003296963A8 (en) Methods and compositions for treating and preventing ear infections
AU2003239132A8 (en) Methods and compositions for preventing and treating microbial infections
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
IL166062A0 (en) Compositions and methods for therapeutic treatment
IL175579A0 (en) Epithelium treatment methods and devices for treating the epithelium
AU2003275069A8 (en) Compositions and methods for preventing infection
AU2003303948A8 (en) Compositions and methods for preventing infection
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
AU2003237088A8 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
AU2003275433A8 (en) Compositions and methods for treating pain
AU2003254129A8 (en) Method and composition for treating and preventing hepatitis b infection and symptoms thereof
AU2003259198A8 (en) Method and composition for treating and preventing influenza infection and symptoms thereof

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees